Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.33 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051004 | 1.00 | FBP1 (0.34) | FBP1SMPD1AMDHD2 | |
| SCHEMBL10005831 | 1.00 | FBP1 (0.34) | FBP1SMPD1AMDHD2 | |
| SCHEMBL16996706 | 0.92 | FBP1 (0.36) | FBP1AMDHD2 | |
| SCHEMBL13172425 | 0.92 | FBP1 (0.36) | FBP1AMDHD2 | |
| SCHEMBL12523685 | 0.89 | SMPD1 (0.41) | SMPD1 | |
| SCHEMBL15964500 | 0.88 | SMPD1 (0.31) | FBP1SMPD1 | |
| SCHEMBL17209504 | 0.88 | — | — | |
| SCHEMBL17208119 | 0.88 | — | — | |
| SCHEMBL21202645 | 0.87 | SMPD1 (0.30) | FBP1SMPD1 | |
| SCHEMBL21474777 | 0.87 | SMPD1 (0.30) | FBP1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20190314401-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2019-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | FBP1 2143/4885SMPD1 2087/4885AMDHD2 3263/4885 |
| US-20190314401-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | FBP1 2143/4885SMPD1 2087/4885AMDHD2 3263/4885 |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | FBP1 2143/4885SMPD1 2087/4885AMDHD2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.